Related Experiment Videos
Recurrent squamous carcinoma of the vulva
A S Tilmans1, G P Sutton, K Y Look
1Department of Radiation Oncology, Indiana University Medical Center, Indianapolis 46202-5274.
American Journal of Obstetrics and Gynecology
|November 1, 1992
Summary
Recurrent vulvar cancer requires careful follow-up. While local recurrences can be treated, distant spread often proves fatal, emphasizing the need for prompt restaging and salvage therapy.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
Background:
- Recurrent squamous cell carcinoma of the vulva presents a significant clinical challenge.
- Understanding recurrence patterns and salvage therapy efficacy is crucial for improving patient outcomes.
Purpose of the Study:
- To review the experience at Indiana University with recurrent vulvar squamous cell carcinoma over an 18-year period.
- To evaluate the patterns, timing, and salvage treatment outcomes for vulvar cancer recurrence in relation to primary tumor characteristics.
Main Methods:
- Retrospective analysis of 40 patients with invasive squamous cell carcinoma of the vulva.
- Review of 21 patients who underwent primary therapy at Indiana University between 1971 and 1989.
Main Results:
- Recurrences were observed in 17 patients (43%) at the vulva, 12 (30%) in the groin, 2 (5%) in the pelvis, and 9 (22.5%) distantly.
- Salvage therapy was successful in 62.5% of patients, with survival varying by recurrence site, tumor grade, and time to recurrence.
- Optimal outcomes were associated with early-stage disease, grade 1 tumors, local recurrence, and recurrence >16 months after initial treatment.
Conclusions:
- Long-term follow-up and restaging are essential for patients with vulvar cancer.
- Local and nodal recurrences can often be managed with surgery and/or radiotherapy.
- Regional and distant recurrences generally have a poor prognosis, highlighting the importance of early detection and intervention.